US Patent

US8323671 — Prolyl hydroxylase inhibitors and methods of use

Method of Use · Assigned to Akebia Therapeutics Inc · Expires 2028-04-03 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using prolyl hydroxylase inhibitors, such as vandetabine (vadadustat), to treat conditions including Peripheral Vascular Disease and heart failure.

USPTO Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3876 — vadadustat
U-3876 — vadadustat
U-3876 — vadadustat

Patent Metadata

Patent number
US8323671
Jurisdiction
US
Classification
Method of Use
Expires
2028-04-03
Drug substance claim
No
Drug product claim
No
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.